Study on the Application of Percutaneous Coronary Intervention in Patients with Chronic Coronary Syndrome Combined with Renal Disease

Objective: To analyze the clinical effect of percutaneous coronary intervention in the treatment of chronic coronary syndrome combined with kidney disease. Methods: 150 patients with chronic coronary syndrome combined with renal disease admitted to a hospital from June 2023 to May 2024 were selected, and were divided into the control group and the observation group, 75 cases each, using the mean score method. The control group implemented conventional drug (clopidogrel, aspirin, statins) treatment, and the observation group implemented percutaneous coronary intervention on this basis, comparing the two groups’ treatment effects. Results: The mortality rate (9.33%) and the deterioration rate of renal function (5.33%) of patients in the observation group during the treatment period were significantly lower than those of the control group (21.33%) and (16.00%). The average hospitalization time of patients in the observation group was shorter than that of the control group (15.75 ± 4.24) days. The recurrence rate of angina pectoris of the patients of the observation group in the three months after discharge from the hospital was lower than that of the control group (25.33%) and that of the observation group was lower than that of the control group (6.67%), the difference was statistically significant (P < 0.05). Before treatment, there was no statistically significant difference in the levels of LVEDD, LVESD, and LVEF between the two groups (P > 0.05). After three months of treatment, the LVEDD (52.55 ± 4.02) mm and LVESD (41.44 ± 2.17) mm in the patients of the observation group were lower than those of the control group (57.37 ± 3.74) mm and (46.44 ± 2.59) mm; LVEF (50.78 ± 5.97)% of patients in the observation group was higher than that of (43.06 ± 5.92)% in the control group, and the difference was statistically significant (P < 0.05). Before treatment, there was no statistically significant difference in the levels of CK-MB and cTnI between the two groups (P > 0.05). At 24h and 72h after treatment, the levels of CK-MB and cTnI in patients of the observation group and the control group were (35.21 ± 9.81) U/L, (1.24 ± 0.34) μg/L, (13.19 ± 5.12) U/L, (0.36 ± 0.08) μg/L and (38.79 ± 10.84) U/L, (1.45 ± 0.32) μg/L, (19.87 ± 4.76) μg/L, (0.58 ± 0.11) μg/L, the difference was statistically significant (P < 0.05). Conclusion: Percutaneous coronary intervention is effective in treating chronic coronary syndrome combined with renal disease, which can significantly improve the level of a patient’s cardiac function and reduce the level of CK-MB and cTnI, and is worth being widely used in clinical practice.